Anti-SS-A and SS-B antibodies

Discovery and nomenclature of anti-SS-A and anti-SS-B antibodies In 1961, Anderson et al. identified two immunologically different antibodies in the serum of patients with Sjogren's syndrome (SS), referred to as SjT and SjD antibodies, respectively. Later, Reichlin et al found similar antibodies in the serum of patients with systemic lupus erythematosus (SLE), named Ro and La antibodies. In 1975, Alspangh and Tan studied the activity of these two new antibodies in the serum of SS patients, and said the two antibodies were SS-A antibody and SS-B antibody. The relevant international laboratories were sero-exchanged. In 1979, it was finally confirmed that SS-A was actually Ro, and SS-B was La. Basic Information Specialist classification: growth and development check classification: immunological examination Applicable gender: whether men and women apply fasting: fasting Analysis results: Below normal: Normal value: no Above normal: negative: normal. Positive: The possibility of illness is high. Tips: Do not eat anti-inflammatory drugs, check blood on an empty stomach. Normal value Normal people are negative. Clinical significance Abnormal results: According to the sensitivity of the method, the anti-SS-A (Ro) positive rate in patients with primary Sjogren's syndrome can reach 70% to 100%, and in SLE is 24% to 60%. Patients with anti-SS-A-positive SLE often have Sjogren's syndrome or photo-sensitive disease, especially when antibodies are high titers. Anti-SS-B (La) is also usually positive in these cases, and there is evidence that it is often distinguished from primary Sjogren's syndrome, although this is not well understood. Patients with primary Sjogren's syndrome who are anti-SS-A and anti-SS-B positive usually exhibit more in vitro symptoms of the gland, such as vasculitis and lymphadenopathy. Patients with SLE variants, such as subacute cutaneous lupus (70% to 90%), SLE with complement C2 or C4 deficiency (50% to 90%), have an overall anti-SS-A (Ro) positive rate. Typical SLE patients are high, and in these cases, anti-SS-B (La) is usually undetectable. In 1% of patients with SLE, ANA cannot be detected even during the active period, but anti-SS-A (Ro) can be detected in 60% of such cases. The people who need to be examined are: neonatal lupus, patients with congenital heart disease. Positive results may be diseases: lupus erythematosus, congenital heart disease considerations Forbidden before examination: Do not eat anti-inflammatory drugs, check blood on an empty stomach. Requirements for inspection: Note that serum samples are not contaminated and sent to the test in time. And follow the doctor's request. Inspection process OBJECTIVE: To evaluate the performance of enzyme-linked immunosorbent assay (ELISA) for the detection of antinuclear antibodies and anti-saline extractable nuclear antigen (ENA) antibodies. METHODS: ELISA reagents associated with purified antigen and indirect immunofluorescent antinuclear antibody (IFANA) assay, immunoblotting (IBT) and convective immunoelectrophoresis (CIE) were used for 20 systemic lupus erythematosus (SLE), Detection of autoantibodies in 10 Sjogren's syndrome (SS) patients and 30 healthy controls. RESULTS: There was no significant difference in sensitivity and specificity between ELISA and IFANA antinuclear antibody screening tests for the diagnosis of connective tissue disease (P>0.05), but 5 patients with IFANA negative and ELISA positive were identified as anti-SS-A and / or dsDNA antibody positive; 1 ELISA positive and IFANA negative normal human serum confirmed to be false positive ELISA test. The specificity of anti-Sm antibody detected by ELISA, CIE and IBT was 100%, and the sensitivity difference was not significant (P>0.05). Compared with IBT, ELISA was more sensitive to anti-SS-A antibody detection (P<0.01). ELISA was more sensitive to anti-SS-B antibody than CIE (P<0.05). Conclusion The ELISA anti-nuclear antibody detection reagent used in this study is sensitive and specific. Not suitable for the crowd Inappropriate people: no special requirements. Adverse reactions and risks There are no related complications and hazards.

The material in this site is intended to be of general informational use and is not intended to constitute medical advice, probable diagnosis, or recommended treatments.